So-Young International AI Stock Analysis
Want to see SY full AI Analyst Report?
So-Young International (SY) AI Stock Analysis
So-Young International
(NASDAQ:SY)
The overall score is 55, reflecting a company in transition. The primary positive driver is a powerful operational turnaround in its aesthetic treatment business, as detailed in the latest earnings call, which is supported by bullish technical momentum. However, these strengths are significantly offset by a legacy of poor financial health, characterized by persistent net losses, negative cash flows, and a negative P/E ratio. The company's future hinges on the core clinic business's growth and margin expansion overcoming the drag from declining legacy segments.
So-Young International (SY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $264.21M
- Dividend Yield
- ―
- Average Volume (3M)
- 515.45K
- Price to Earnings (P/E)
- -7.3
- Beta (1Y)
- 1.07
- Revenue Growth
- 30.18%
- EPS Growth
- 61.28%
- Country
- US
- Employees
- 2,348
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
So-Young International Business Overview & Revenue Model
Company Description
So-Young International Inc. manages a digital platform specializing in medical aesthetics and elective healthcare services, serving customers in the People's Republic of China and globally. This online ecosystem enables users to explore content, shar...
So-Young International Earnings Call Summary
The call was strongly positive. The company reported record group revenue, approximately 130% year-over-year aesthetic treatment growth, a 37% year-over-year reduction in net loss, improved gross margin, higher same-store sales, expanding clinic profitability and positive operating cash flow across most centers. Management also presented continued product, physician, supply chain and AI initiatives, along with strong revenue guidance for the next quarter. The main negatives were declines in non-clinic business lines, higher cost of revenues and operating expenses, and the continuation of a group-level net loss.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For Q3 2026, So-Young expects revenues from aesthetic treatment services to be between RMB 352 million and RMB 362 million, representing year-over-year growth of 91.7% to 97.2%; it expects meaningful margin expansion at aesthetic centers, has raised its capacity utilization benchmark by 50% from 10 treatments per bed per day to 15, expects to see substantial continued improvement in clinic gross margins in Q3 and Q4 of this year, plans to roll out its first generation of fully intelligent centers in Q4 this year, and has a robust pipeline of new products over the next 2 years to help improve gross margin.
So-Young International Financial Statement Overview
Summary
Financial health is severely stressed. The income statement shows deep net losses and gross margins halved to 47.8%. Cash flow is critically weak, with four consecutive years of negative free cash flow and a -20.4% FCF margin in 2025. The balance sheet is deteriorating with shrinking equity, though leverage remains manageable. Overall, the company is burning cash and eroding shareholder value.
Income Statement
20Very NegativeBalance Sheet
40NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.48B | 1.47B | 1.50B | 1.26B | 1.69B |
| Gross Profit | 759.68M | 707.86M | 899.11M | 953.69M | 864.58M | 1.36B |
| EBITDA | -203.21M | -182.19M | -38.56M | 53.96M | -39.99M | 63.39M |
| Net Income | -256.54M | -235.70M | -589.53M | 21.28M | -65.55M | -8.37M |
Balance Sheet | ||||||
| Total Assets | 2.65B | 2.65B | 2.74B | 3.21B | 3.20B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 876.69M | 936.96M | 1.19B | 1.33B | 1.57B | 1.74B |
| Total Debt | 379.00M | 299.90M | 239.88M | 145.77M | 71.26M | 105.89M |
| Total Liabilities | 1.05B | 981.44M | 776.43M | 653.25M | 590.00M | 813.33M |
| Stockholders Equity | 1.49B | 1.55B | 1.84B | 2.44B | 2.50B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | -302.01M | -302.01M | -88.18M | -28.68M | -128.58M | 39.23M |
| Operating Cash Flow | -105.39M | -105.39M | -25.63M | 22.50M | -112.87M | 84.29M |
| Investing Cash Flow | -42.81M | -42.81M | 257.04M | -202.61M | -572.21M | 339.82M |
| Financing Cash Flow | -63.70M | -63.70M | -21.51M | -100.02M | -13.59M | -216.74M |
So-Young International Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SY, the sentiment is Negative. The current price of 2.02 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.42, and below the 200-day MA of 2.47, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 32.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SY.
So-Young International Risk Analysis
So-Young International disclosed 86 risk factors in its most recent earnings report. So-Young International reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskSo-Young International Peers Comparison
Overall Rating
PHR69Neutral
CCLD66Neutral
GDRX65Neutral
AMWL57Neutral
TDOC56Neutral
SY55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $787.68M | 73.69 | 3.01% | ― | 12.93% | ― | |
| 66Neutral | $102.97M | 18.64 | 24.48% | ― | 14.86% | 214.99% | |
| 65Neutral | $1.21B | 67.68 | 2.61% | ― | -1.83% | -48.77% | |
| 57Neutral | $202.17M | -3.41 | -25.49% | ― | -20.30% | 52.30% | |
| 56Neutral | $1.60B | -10.23 | -11.63% | ― | -2.38% | 32.73% | |
| 55Neutral | $203.24M | -7.33 | -15.75% | ― | 30.18% | 61.28% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SY | So-Young International | 2.02 | -1.47 | -42.12% | |
| CCLD | Carecloud, Inc. | 2.42 | -0.56 | -18.79% | |
| TDOC | Teladoc Inc. | 8.80 | 1.80 | 25.71% | |
| PHR | Phreesia | 12.69 | -6.91 | -35.26% | |
| AMWL | American Well Corporation | 11.74 | 7.72 | 192.04% | |
| GDRX | Goodrx Holdings, Inc. | 3.56 | 0.77 | 27.60% |
So-Young International Corporate Events
So-Young International Posts Record Q2 2026 Revenue as Aesthetic Treatment Business Surges
For the second quarter ended June 30, 2026, So-Young reported total revenues of RMB505.2 million, up 33.4% year-on-year and reaching a record level, driven mainly by a 129.5% surge in aesthetic treatment services revenue to RMB331.4 million. Despite...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026
